Company / Shareholders' Equity
Edesa Biotech, Inc. Shareholders' Equity History
FY2014-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$6.6M
FY2021
5-year range
-$2.2M / $12.3M
FY2017-FY2021
Trend
+26.2%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity returned to growth in FY2021 after 2 years of decline, reaching $7M.
Based on SEC 10-K filings.
$7M in FY2021 with a 3-year CAGR of -3.6%.
Declined from $7M to $7M over the past 3 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -3.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -3.6%, indicating a declining trend.
- In FY2021, shareholders' equity increased 26.2% year-over-year.
- Peak shareholders' equity was recorded in FY2017.
- Lowest shareholders' equity in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $6.6M | +26.2% |
| FY2020 | $5.3M | -29.0% |
| FY2018 | $7.4M | -39.9% |
| FY2017 | $12.3M | +660.8% |
| FY2016 | -$2.2M | +0.0% |
| FY2015 | -$2.2M | -343.4% |
| FY2014 | $902.2K | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026